Joint letter with the Competition and Markets Authority: pricing during the COVID-19 pandemic

Our Chief Executive and the Chief Executive Officer of the Competition and Markets Authority have written a joint letter to pharmacy owners and superintendent pharmacists in Great Britain.

The letter highlights that both regulators have received reports alleging that a small minority of pharmacies are seeking to benefit from the coronavirus pandemic by charging unjustifiably high prices for essential products.

The letter explains the General Pharmaceutical Council’s and the Competition and Markets Authority’s respective roles and expectations as regulators in relation to this important issue during the pandemic.

Read the letter in full